Other names: Bactroban; Mupirocinum; Bactroban Nasal; Pseudomonic acid; 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
Molecular formula: C26H44O9
Molecular weight: 500.62200
Accurate quality: 500.29900
Appearance: white or off-white crystalline powder
The topical external antibiotic used in this product is a substance produced by Pseudomonas fluorescens culture, namely Pseudomonas A. The antiseptic effect is mainly by binding of RNA synthetase with isoleucine, preventing isoleucine infiltration, stopping the synthesis of protein containing isoleucine, and acting as bactericidal or bacteriostasis. This drug shows bacteriostatic action at very low concentration and has bactericidal action at high concentration. This drug is highly sensitive to all gram-positive cocci, especially Staphylococcus and Streptococcus, which are related to skin infection, and is also effective for the drug-resistant Staphylococcus aureus. And for some gram-negative bacteria such as Escherichia coli, Haemophilus influenza, and gonorrhea, it also has certain antibacterial effects. It is not sensitive to most anaerobes and normal skin bacteria. In vitro, the emergence rate of mutant strains is very low.
After being coated with skin, it can penetrate into the stratum corneum, and its binding rate to human serum albumin is 95%. After absorption, it can be rapidly metabolized into inactive first acid (monic acid A) and excreted through the kidneys. When taken orally, it is rapidly metabolized into inactive metabolites after absorption.
It is suitable for skin infections caused by a variety of bacteria, especially gram-positive cocci, such as pustulosis, furuncle, folliculitis and eczema, dermatitis, various types of ulcers and trauma.